USPTO Patent Applications - Organic Chemistry (C07D)

Crystalline Benzamide Salt Forms for T-Type Calcium Channel Diseases

USPTO published patent application US20260092037A1 disclosing crystalline salt forms of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide useful for treating T-type calcium channel diseases including epilepsy, essential tremor, and major depressive disorder. The application (No. 19311876) was filed August 27, 2025, naming inventors David T. Jonaitis and Lisa McCracken.

Indole Derivatives as Serotonergic Agents for CNS Disorders

USPTO published Application US20260092035A1 disclosing indole derivatives of general Formula (I) as serotonergic agents useful for treating CNS disorders including psychosis and mental illnesses. Inventor Abdelmalik Slassi filed the application on December 9, 2025 (Application No. 19413522). This patent application publication represents a routine intellectual property filing with no compliance obligations or regulatory deadlines for third parties.

Heterocyclic Compound Orexin 2 Receptor Agonist Narcolepsy Treatment

The USPTO published patent application US20260092033A1 for a heterocyclic compound as an orexin 2 receptor agonist for treating narcolepsy. Inventors include researchers from a Japanese pharmaceutical company. The application claims priority to Application No. 19287436 filed July 31, 2025. This is a standard pharmaceutical patent filing that does not impose regulatory obligations on third parties.

Ligand-Enabled Scalable C-H Hydroxylation of Benzoic and Phenylacetic Acids at Room Temperature

The USPTO published patent application US20260092029A1 by Yu/Quan et al. disclosing methods for Pd-catalyzed C-H hydroxylation of benzoic and phenylacetic acids at room temperature using bifunctional pyridone-carboxylic acid ligands and aqueous hydrogen peroxide as oxidant. The application, filed September 7, 2023, also covers synthesis of polyfluorinated natural products and ibuprofen hydroxylation.

7-Azaindole Analogs and Serotonin Agonists for Neurological Disorders

The USPTO published patent application US20260092034A1 for 7-azaindole analogs as serotonin receptor agonists for treating neurological disorders. Assigned to Kuleon LLC with inventor David Gilles, the application covers both hallucinogenic and non-hallucinogenic compounds. The patent application was filed December 8, 2025, under application number 19412382.

Crystalline T-type calcium channel salt patent

The USPTO published patent application US20260092036A1 by inventors Daniel Thomas Walters and Thomas San Ie on April 2, 2026. The application discloses Pattern D, a crystalline form of N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide hydrochloride salt trihydrate (Compound 1), along with pharmaceutical compositions and methods for treating neurological and psychiatric disorders. The application was originally filed on August 27, 2025, with application number 19311030.

VMAT2 Inhibitor Heterocyclic Compound and Preparation Method

The USPTO published patent application US20260091029A1 for a class of VMAT2 inhibitor heterocyclic compounds. The application, filed December 9, 2025 under Application No. 19414124, covers compounds represented by formula (I), their stereoisomers, and pharmaceutically acceptable salts. The inventors (Jingwei Tian, Rui Zhang, and seven others) also disclose preparation methods and applications for treating diseases related to VMAT2 and Sigma-1 receptors.

KRAS Inhibitor Heterocyclic Compounds for Cancer Treatment

USPTO published patent application US20260092075A1 for KRAS inhibitor heterocyclic compounds designed for cancer treatment. The application covers novel chemical compounds of specified formula, their pharmaceutical salts, and methods of using these compounds for treating cancer patients. Filing date was September 30, 2025.

Novel Heterocyclic Compounds for Pharmaceutical Use

Hoffmann-La Roche Inc. published patent application US20260092076A1 for novel heterocyclic compounds with pharmaceutical use. The application covers compounds having general formula I with defined R1, R2, R3, A and W substituents, related compositions, and methods of using the compounds. Filing date was October 7, 2025, under Application No. 19351608.

Bifunctional degraders with electrophilic PROTACs

The USPTO has published a patent application (US20260083722A1) detailing bifunctional degraders comprising electrophilic PROTACs that engage DCAF1. The application was filed on May 19, 2023, and published with a projected application date of March 26, 2026.

Salts and Solid Forms of 4-hydroxy-N,N-diisopropyltryptamine

The USPTO has published a patent application detailing new salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DIPT), including hemi-glutarate and hemi-succinate forms. These forms are disclosed for their potential use in treating neurological and psychiatric disorders.

Method for Preparing Indigo or Substituted Derivative

The USPTO has published a patent application (US20260085042A1) detailing a method for synthesizing indigo or substituted derivatives. The application, filed on June 16, 2023, describes a process involving anthranilic acid and glyoxylic acid under hydrogenation with a metal catalyst.

Patent Application: Initiator Mixture and Polymer Composition

The USPTO has published a new patent application (US20260085043A1) detailing an initiator mixture, a composition including it, and a polymer formed from the composition. The application was filed on September 18, 2025, by inventors from South Korea.

Patent Application for 4-Amino-5-Methyl Pyridin-2-One Production Process

The USPTO has published a patent application (US20260085044A1) detailing an improved process for producing 4-amino-5-methyl-(1H)-pyridin-2-one and its derivatives. The application, filed by MinAscent Technologies GmbH, describes a method using ammonium salts under pressure without gaseous ammonia, aiming for high yield and purity while reducing container corrosion.

Patent Application for Nitrogen-Containing Heterocyclic Derivative Inhibitor

The USPTO has published a patent application (US20260085045A1) for a nitrogen-containing heterocyclic derivative inhibitor. The application details a compound, its preparation method, and its use in treating diseases such as cardiovascular and cerebrovascular conditions.

Patent Application: Dual Function Compounds for Cancer Treatment

The USPTO has published patent application US20260085046A1, filed on August 7, 2025, for dual function compounds intended for cancer treatment. The application discloses compounds of Formula (I) and their use in treating cancer.

Triphenylazole Compound Patent Application for Synucleinopathy Treatment

The USPTO has published a patent application (US20260085047A1) filed by Shiratori Pharmaceutical Co., Ltd. for a triphenylazole compound intended for the treatment or prevention of synucleinopathy. The application details the compound's structure and its potential use in pharmaceutical compositions.

ACSS2 Inhibitors for Cancer, Alcoholism, Viral Infections

The USPTO has published a patent application (US20260085048A1) detailing novel ACSS2 inhibitors and their potential uses in treating cancer, alcoholism, and viral infections. The application was filed on September 8, 2025.

Ergothioneine Crystal Form Patent Application

The USPTO has published a patent application (US20260085049A1) for a novel crystal form of ergothioneine and its preparation method. The application details a method for producing high-purity ergothioneine with low moisture content, intended for use in dietary supplements, foods, and cosmetics.

Triple Kinase Inhibitors for Cancer Treatment

The USPTO has published a patent application (US20260085050A1) for triple kinase inhibitor compounds designed for cancer treatment. The application details compounds that inhibit EGFR, ALK, and MET simultaneously, along with methods for treating cancer using these inhibitors.

Patent Application for 2-Chloro-4-Fluoro-5-Nitrobenzoic Acid Preparation

The USPTO has published a patent application (US20260085051A1) detailing a novel nitration process for preparing 2-chloro-4-fluoro-5-nitrobenzoic acid. The assignee is ADAMA AGAN LTD. This compound is used in the synthesis of the herbicide saflufenacil.

Patent Application for Furan Derivative Oxidation Process

The USPTO has published a patent application (US20260085052A1) detailing a new process for producing 2,5-furandicarboxylic acid. The application, filed by David Lee Sikkenga and Jan Hendrik Blank, describes a specific oxidation method involving furan derivatives, oxidants, solvents, and catalysts.

Patent Application for Benzofuran Derivatives as SIK Inhibitors

The USPTO has published a patent application (US20260085053A1) from BEONE MEDICINES I GMBH for benzofuran derivatives that act as SIK inhibitors. These compounds are intended for the treatment of various inflammatory diseases.

Hispidin Derivative Synthesis Method and Use

The USPTO has published a patent application (US20260085054A1) detailing a new method for synthesizing Hispidin derivatives and their use in preparing lipid-lowering drugs. The application describes a process using readily available starting materials with potential for large-scale industrial application.

Patent Application for Recyclable Polymer Material and Monomer

The USPTO has published a patent application (US20260085055A1) for a novel monomer and a chemically recyclable polymer material comprising the same. The application, filed by the Korea Institute of Science and Technology, describes a monomer formed by bonding a pentagonal cyclic olefin molecule with a photosensitive molecule to enable chemical recycling.

OX1 Receptor Antagonists Patent Application

The USPTO has published a new patent application (US20260085056A1) filed on May 9, 2025, by NXERA PHARMA UK LIMITED. The application relates to novel compounds for treating neurological or psychiatric disorders associated with orexin receptors.

Substituted Indazoles for Treating Animal Allergic Inflammatory Diseases

The USPTO has published a patent application detailing the use of substituted indazoles for the treatment and prevention of allergic and inflammatory diseases in animals. The application, filed on October 9, 2025, outlines specific compounds and their potential applications in veterinary medicine.

Patent Application US20260085058A1 for SOS1 Degraders Treating Cancers

The USPTO has published patent application US20260085058A1, which relates to compounds that degrade son of sevenless homolog 1 (SOS1) and their use in treating cancers, particularly KRAS-mutant cancers. The application was filed on August 11, 2023.

System for updating medical facility uses AI

The USPTO has published a patent application for a system that uses AI to determine whether to update a medical facility. The system retrieves information from the facility, applies an AI model, and initiates maintenance or upgrades based on the determination. The application was filed on September 4, 2023.

Patent Application: Therapeutic Compounds - Orexin-1 Receptor Antagonists

The USPTO has published a new patent application (US20260085060A1) for therapeutic compounds that act as orexin-1 receptor antagonists. The application, filed on September 25, 2025, details compounds with structural formula (I), their preparation, and pharmaceutical uses.

Patent Application: Phthalazine Derivatives as Pyruvate Kinase Modulators

The USPTO has published a new patent application (US20260085061A1) for phthalazine derivatives as pyruvate kinase modulators, assigned to Sitryx Therapeutics Limited. The application was filed on September 25, 2025.

Novel compounds as CK2 inhibitors for disease treatment

The USPTO has published a patent application (US20260085062A1) for novel compounds identified as CK2 inhibitors. These compounds are intended for the treatment and prevention of various diseases, including cancer, viral infections, and neurodegenerative disorders. The application details specific chemical structures and their potential pharmaceutical uses.

Patent Application: Benzamide Compounds for SARS-CoV-2 PLpro Inhibition

The USPTO has published a new patent application (US20260085063A1) detailing benzamide compounds and methods for inhibiting SARS-CoV-2 PLpro. The application was filed on August 19, 2025, by inventors Jun Wang, Bin Tan, and Prakash Daulat Jadhav.

Patent Application: Benzofuranyl/Benzoxazolyl Compounds for Cancer Treatment

The USPTO has published a patent application (US20260085064A1) for substituted benzofuranyl and benzoxazolyl compounds, including their synthesis and use in treating cancer. The application was filed on May 2, 2025, by inventors from institutions including the University of Texas MD Anderson Cancer Center.

Patent for SGLT Inhibitor Synthesis Intermediate

The USPTO has published a patent application for a crystalline form of an intermediate useful in the synthesis of SGLT inhibitors. The application details a method to improve purification efficiency and minimize related substances in the final product, potentially increasing yield.

LRRK2 Degrading Compounds for Parkinson's Disease Treatment

The USPTO has published a new patent application (US20260085066A1) detailing bifunctional compounds designed to degrade LRRK2, a protein implicated in Parkinson's Disease. The application covers pharmaceutical compositions and methods for treating LRRK2-associated disorders.

Cyclic Sulfonamide RNR Inhibitors for Cancer Treatment

The USPTO has published a new patent application, US20260085067A1, detailing cyclic sulfonamide RNR inhibitors for cancer treatment. The application was filed on September 12, 2023, by inventors Anthony B. Pinkerton, Jacques Mauger, and Yen Pham Hong Truong.

Pritelivir Crystalline Form Patent Application

The USPTO has published a patent application (US20260085068A1) filed by Assembly Biosciences, Inc. on August 28, 2023. The application describes a novel crystalline form of the antiviral drug pritelivir, intended for the treatment of herpes virus.

USPTO Patent Application for Cancer Prodrugs

The USPTO has published a patent application (US20260085069A1) for novel prodrug compounds designed to treat cancer and other diseases by inhibiting Casein Kinase 2 alpha (CK2α). The application details specific chemical structures and their potential pharmaceutical uses.

Patent Application for Cancer Treatment Compounds

The USPTO has published a new patent application (US20260085070A1) for heterocyclic CBL-B inhibitors intended for the treatment of cancer. The application was filed on April 7, 2025, by inventors Yingzhi BI, Kenneth G. CARSON, and Geraldine Cirillo HARRIMAN.

Patent Application for Novel Crystalline Form of Amine Compound

The USPTO has published a patent application (US20260085071A1) for novel crystalline forms of an amine compound, 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine. The application also discloses pharmaceutical compositions and the use of these forms for treating diseases such as atopic dermatitis and urticaria.

Method for Preparing Intermediate of Adrenergic Receptor Agonist

The USPTO has published a patent application detailing a new method for preparing an intermediate of an adrenergic receptor agonist. The method claims to offer improved yield, reduced cost, and milder reaction conditions, making it more favorable for commercial production. The application was filed on December 4, 2025.

Patent Application for Pyrazolylcarboxamide Compounds for Therapy

The USPTO has published a patent application (US20260085073A1) for pyrazolylcarboxamide compounds and their use in therapy. The application details compounds that inhibit MALT1 and their potential treatment for proliferative, inflammatory, or autoimmune disorders.

Patent Application: Cancer Treatment Compositions and Methods

The USPTO has published a patent application (US20260085074A1) detailing compositions and methods for treating cancer by modulating K-Ras, a frequently mutated oncogene. The application was filed on June 17, 2025, by inventors Jonathan Ostrem, Ulf Peters, and Kevan M. Shokat.

Protein Degraders Patent Application

The USPTO has published a new patent application, US20260085075A1, related to protein degraders and their uses. The application was filed on August 19, 2025, by inventors Nello Mainolfi, Nan Ji, Yi Zhang, and Matthew M. Weiss.

Patent Application for Crystal Form of Aromatic Heterocyclic Compound

The USPTO has published a patent application (US20260085076A1) detailing a new crystal form (I and III) of an aromatic heterocyclic compound. The application also describes a production method and its use in treating diseases related to abnormal JAK-STAT signaling pathways.

Patent Application: Janus Kinase Inhibitors by Chiesi Farmaceutici

The USPTO has published a patent application (US20260085077A1) filed by Chiesi Farmaceutici S.P.A. The application describes compounds of general formula (I) that inhibit Janus Kinase (JAK) family kinases. These compounds are intended for therapeutic use in treating inflammatory diseases.

KDM1A Inhibitors for Disease Treatment Patent Application

The USPTO has published a new patent application (US20260085082A1) from Imago Biosciences, Inc. The application discloses new compounds and compositions for pharmaceutical use, specifically for inhibiting KDM1A and increasing gamma globin gene expression to treat diseases like acute myelogenous leukemia.

Patent Application for Novel Compound Treating Neurodegeneration and Cardiovascular Diseases

The USPTO has published a patent application (US20260085083A1) for a novel compound and pharmaceutical composition developed by SHANDONG RUZHI BIOMEDICINE TECHNOLOGY CO., LTD. The compound is intended for preventing or treating neurodegenerative diseases and cardiovascular/cerebrovascular diseases.

New Polymers and Methods Patent Application

The USPTO has published a new patent application, US20260085336A1, detailing processes for forming pyridinedicarboxylic acid derivatives and copolymers. The application, filed on September 25, 2025, outlines biocatalytic methods and potential uses for these new materials.